CatalystMarker
← board

MCUJF

Medicuredistress 1/10 · well-funded / low risk
$0.840%today-12% from 52w high
medicure.comFounded 1997Winnipeg, MBDrug Manufacturers - Specialty & Generic
Lead: Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Revenue
pre-revenue
Liquidity
$2M
Runway
2.8 yrs
Shares 1y
0%

Price & events

-10.6% over 6M
$0.67$0.81$0.96Jan 26Apr 26Jul 2616k
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+25.4%
1W
+25.4%
1M
-12.5%
3M
-10.6%
6M
+3.7%
1Y
+13.5%
2Y
-13.4%
5Y
-12.5%
All

Overview

Market Cap
$8.77M
Volume
200
52 Week Range
$0.67 – $0.96
Total Shares
10.44M
Float Shares
5.27M
% Held by Insiders
27.30%
% Held by Institutions
23.10%
RVOL
0.47x
Beta
1.04

Pipeline stages · 1 programs

Pyridoxal Phosphate
Preclin
Ph1
Ph2
Ph3
Filed
PDUFA
Approved
next 2026-11

Pipeline · 1 trials · 1 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-11
Estimated 50%
readout ~2027-01-15
Phase 3Pyridoxal PhosphatePyridox(am)Ine 5'-Phosphate Oxidase Deficiencyrecruiting

Catalyst news & presentations · 1

Approved drugs (3)

  • ZYPITAMAGPITAVASTATIN MAGNESIUM2017 · Prescription
  • AGGRASTATTIROFIBAN HYDROCHLORIDE1998 · Prescription
  • AGGRASTATTIROFIBAN HYDROCHLORIDE1998 · Prescription

Capital structure — dilution & financing

Shares out: 10,436,313 · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors — Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.